Thyroid Hormone Treatment and Breast Cancer Risk in Women: A Systematic Review and Meta-Analysis of Observational Studies
Authors:
- Stylianos KopanosSKStylianos Kopanos
- Jasper David FeldkampJFJasper David Feldkamp
- Johanna TyssenJTJohanna Tyssen
- Xinjun LiXLXinjun Li
- Kristina SundquistKSKristina Sundquist
- Carolina Pape-KöhlerCPCarolina Pape-Köhler
- Marcel BinneböselMBMarcel Binnebösel
- Annika HoyerAHAnnika Hoyer
- Per WändellPWPer Wändell
- Joachim FeldkampJFJoachim Feldkamp
Open Access
- 2 July 2026
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 16 (7) , 465
Abstract
Objective: Thyroid hormone treatment is the standard therapy for hypothyroidism, particularly in women. Concerns have been raised that exogenous thyroid hormone use may increase breast cancer risk, but evidence remains inconclusive. This study aimed to systematically review and synthesize observational evidence on the association between thyroid hormone treatment and breast cancer risk in women. Design: We conducted a systematic review and meta-analysis of observational studies. Methods: MEDLINE, EMBASE, and Web of Science were searched from January 1976 to February 2025. Eligible studies assessed breast cancer incidence in adult women receiving thyroid hormone treatment versus non-users. Pooled ORs were calculated. Findings from cohort studies reporting hazard ratios were synthesized qualitatively. Heterogeneity, publication bias, and certainty of evidence were assessed. PROSPERO ID: CRD42022348966. Results: Four case–control studies including 221,254 women receiving thyroid hormone treatment and 4,385,666 controls were included in the prespecified primary OR-based meta-analysis. In the primary random-effects meta-analysis, thyroid hormone treatment showed a possible epidemiological signal with breast cancer risk (OR 1.43, 95% CI: 0.90–2.28; I2 = 94.3%), although the confidence interval crossed unity and heterogeneity was substantial. Formal assessment of publication bias was performed but should be interpreted cautiously given the small number of included studies. The certainty of evidence was rated as low due to heterogeneity, serious inconsistency and imprecision. Conclusions: Thyroid hormone treatment was associated with a possible epidemiological signal for breast cancer in observational studies; however, the primary pooled estimate was not statistically significant and should be interpreted as hypothesis-generating because of substantial heterogeneity and residual confounding. Further well-designed prospective studies are required before causal or clinical inferences can be made.Keywords
This publication has 38 references indexed in Scilit:
- Prospective evaluation of circulating plasma thyroid hormones concentrations and breast cancer risk in the EPIC cohortEBioMedicine, 2025
- Trends in the use of thyroid diagnostics and treatments between 2008 and 2019 in GermanyScientific Reports, 2024
- Liothyronine Use in Hypothyroidism and its Effects on Cancer and MortalityThyroid®, 2021
- Thyroid Hormone in the Clinic and Breast CancerDiscover Oncology, 2018
- Thyroid Hormone Therapy for Older Adults with Subclinical HypothyroidismNew England Journal of Medicine, 2017
- Thyroid Hormone, Cancer, and ApoptosisComprehensive Physiology, 2016
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Use of thyroid supplements in relation to the risk of breast cancerJAMA, 1980
- Thyroid supplementation for hypothyroidism. An latrogenic cause of breast cancer?JAMA, 1977
- Breast CancerJAMA, 1976